Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STROBE: HRD Status and Benefit from Olaparib + Bevacizumab in Advanced Ovarian Cancer
2024-517363-24-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and bevacizumab in High-Grade Serous Ovarian Cancer (HGSOC), Endometrioid Cystadenocarcinoma, fallopian tube cancer (PFTC) and 1 more, sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Percentage of HR status agreement between VHIO-CARD-300 test and SOPHiA DDM Dx HRD Solution. Planned start Nov 2024; status: authorised.
02
Drugs
olaparibbevacizumab
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)Endometrioid Cystadenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-517363-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517363-24-00.